BioSpace News Archive

SEngine Precision Medicine, a precision oncology company revolutionizing cancer therapies by pre-testing drugs on patient-derived tumor organoids, today presented data from a study summarizing the predictive value of the PARIS® Test in breast cancer tumors as a poster session (PS04/01) at the 2020 San Antonio Breast Cancer Symposium, taking place virtually from December 8-11, 2020.

- European presence represents an important milestone in Taiho Oncology’s expanding global pharmaceutical operations

Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced Chairman, Chief Executive Officer and President of Quanterix, and Founder, Powering Precision Health , Kevin Hrusovsky will present at the Contagion Conference being held on Dec. 10, 2020. The conference will focus on COVID-19 testing and will mark the launch of The Virus Project,

Fresenius Kabi and Kit Check today announced the companies have entered into an agreement under which Fresenius Kabi +RFID™ medications will be read by the Kit Check inventory management solution. The collaboration signals both companies’ commitment to medication safety and quality patient care acr

Amylyx Pharmaceuticals to Present Positive Functional and Survival Data and New Predictive Modeling Results from the CENTAUR Trial in People with ALS at the 31 st International Symposium on ALS/MND - Administration of AMX0035 Is Associated with a Statistically Significant Retention of Functional Abilities and Long-Term Survival Benefit in People Living with ALS

SwabTek offers easy-to-use, safe and affordable narcotics field tests that help governments, airports, schools, corporations and consumers fight the drug crisis. In light of growing drug abuse during the pandemic, SwabTek is expanding its line of innovative presumptive test kits with new, in-demand tests such as Fentanyl+ and Nicotine+ . This press release features multimedia. View the full release here: https://www.bu

Highland Therapeutics Inc. (“Highland”) today announced the appointment of Stephanie C. Read to its Board of Directors, effective November 13, 2020. Ms. Read brings to the Company a wealth of experience and expertise gained from over twenty years of tenure in the pharmaceuticals industry, including in the ADHD market. “It is my pleasure to welcome Ms. Read, an accomplished executive, to the Highland Board of Directors,” said

Thanks to advances in science and technology, and an unprecedented level of global cooperation, , Canada reached a critical milestone in its fight against COVID-19 with the authorization of the first COVID-19 vaccine.

Montreal-based Two-Photon Research Inc. announces CAST, a diagnostics platform that changes the way viruses are detected.

Dogs Supplemented with Fortetropin® Experienced Statistically Significant Improvements in LOAD (Liverpool Osteoarthritis in Dogs) Scores